Neurobiological Mechanisms of Memory Loss in Alzheimer s Disease
The MEMOLOAD project will focus on the molecular and biological mechanisms underlying memory loss that occurs in Alzheimer’s disease, the leading cause of dementia and an enormous medical, social and economic challenge to Europe....
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
BFU2011-22740
BASES NEUROFISIOLOGICAS DE LOS EFECTOS DEL PEPTIDO ß¿AMILOID...
70K€
Cerrado
RTI2018-101850-A-I00
DETERMINACION DE LA FUNCION DE LOS ASTROCITOS HUMANOS EN LA...
121K€
Cerrado
ABATSYNAPSE
Evolution of Alzheimer s Disease From dynamics of single sy...
2M€
Cerrado
SAF2010-15676
REGULACION DE LA VIA PIP3 COMO ESTRATEGIA PARA REVERTIR LA D...
145K€
Cerrado
RYC-2008-02333
Mecanismos de eliminacion de beta-amiloide en la enfermedad...
192K€
Cerrado
RYC-2008-02333
Mecanismos de eliminacion de beta-amiloide en la enfermedad...
192K€
Cerrado
Información proyecto MEMOLOAD
Líder del proyecto
ITASUOMEN YLIOPISTO
No se ha especificado una descripción o un objeto social para esta compañía.
TRL
4-5
Presupuesto del proyecto
4M€
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
The MEMOLOAD project will focus on the molecular and biological mechanisms underlying memory loss that occurs in Alzheimer’s disease, the leading cause of dementia and an enormous medical, social and economic challenge to Europe. Several lines of evidence point to accumulation of beta-amyloid peptide (Aß) in the brain as the key pathologic event in the disease. There is growing evidence that Aß causes memory loss by directly or directly interacting with the known key signalling pathways involved in memory consolidation. However, at present the data is fragmentary and consists mainly of single observations in particular models (cell culture, brain slice, in vivo). In most cases, we still lack the evidence that a clear molecular level interaction translates into memory impairment in vivo. The objective of this proposal is to elucidate the molecular level mechanisms by which accumulation of Aß in the brain results in impaired synaptic plasticity and memory loss. The MEMOLOAD consortium consists of a well-balanced mixture of the seven best available European research groups in terms of research experience on both the mechanisms of memory consolidation and the pathophysiology of Alzheimer’s disease. The current research topic is thus the primary research interest of all partners. MEMOLOAD will significantly contribute to a better understanding of brain memory mechanisms at the behavioural, network, synaptic and molecular levels and of dysfunction at all these levels in Alzheimer’s disease (AD). The knowledge acquired during the course of MEMOLOAD will translate into new validated in vitro and in vivo models for the memory impairing effect of Aß and will feed into industrial development leading to new therapies. The output of MEMOLOAD will include both identification of new drug targets and development of novel peptidomimetic compounds that neutralize the deleterious effects of most harmful Aß species.